Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Wolf (Heidelberg, Germany), M. Schneider (Heidelberg, Germany), T. Muley (Heidelberg, Germany), M. Meister (Heidelberg, Germany), F. Herth (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany), N. Kahn (Heidelberg, Germany). Assessment of blood biomarkers in patients with IPF under antifibrotic therapy. 4811

Member's Comments

No comment yet.

Related content which might interest you: Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 ACE and sIL2-R predict lung function improvement in sarcoidosis during methotrexate therapy Source: Annual Congress 2013 –Sarcoidosis Year: 2013 A rejuvenation effect of the antifibrotic therapy correlates with lung function improvement in IPF patients Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation Source: International Congress 2018 – Moving lung transplantation forward Year: 2018 Effect of sildenafil add-on to antifibrotic treatment in IPF patients Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 The role of monocyte count on monitoring patients with Idiopatic Pulmonary Fibrosis  under antifibrotic treatment Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020 Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Plasma biomarkers and response to therapy at exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 39s Year: 2007 Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Circulating endothelial cell levels decrease after vasodilator therapy and are a biomarker of clinical worsening in refractory pulmonary hypertension in children Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Sputum neutrophil monitoring is useful for long-term oxygen therapy in patients with COPD Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Monitoring anti-inflammatory treatments in IPF and related disorders Source: Annual Congress 2004 - Pathobiological methodologies in monitoring immunomodulatory treatments Year: 2004 Outcomes for COPD pharmacological trials: from lung function to biomarkers Source: Eur Respir J 2008; 31: 416-469 Year: 2008